Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.56 |
| ▸ | NPY1R | P25929 | 8/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.56 |
| ▸ | NPY2R | P49146 | 5/20 | 0.56 |
| ▸ | NMUR2 | Q9GZQ4 | 5/20 | 0.56 |
| ▸ | NMUR1 | Q9HB89 | 5/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | DRD1 | P21728 | 1/20 | 0.53 |
| ▸ | GNRHR | P30968 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.53 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29390426 | 0.92 | OPRM1 (0.61) | NPY4RNPY1RNPY5RNPY2RNMUR2 | |
| SCHEMBL30689268 | 0.89 | OPRK1 (0.58) | NPY4RNPY1RNPY5RNPY2RNMUR2 | |
| SCHEMBL30441110 | 0.89 | NMUR2 (0.54) | NPY4RNPY1RNPY5RNPY2RNMUR2 | |
| SCHEMBL31307275 | 0.87 | RAMP3 (0.62) | NPY4RNPY1RNPY5RNPY2RNMUR2 | |
| SCHEMBL29575402 | 0.87 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RNMUR2 | |
| SCHEMBL30634740 | 0.86 | NMUR2 (0.65) | NPY4RNPY1RNPY5RNPY2RNMUR2 | |
| SCHEMBL8019005 | 0.86 | OPRM1 (0.60) | NPY4RNPY1RNPY5RNPY2RNMUR2 | |
| SCHEMBL9852750 | 0.86 | NPY4R (0.58) | NPY4RNPY1RNPY5RNPY2RNMUR2 | |
| SCHEMBL31686488 | 0.86 | RAMP3 (0.53) | NPY4RNPY1RNPY5RNPY2RABCB11 | |
| SCHEMBL29510980 | 0.85 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2RNMUR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12364767-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-07-22 | — | — | US | disclosed |
| CN-115505028-A | Branched polyethylene glycol linker and application thereof | 辽宁键凯科技有限公司 | 2022-12-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12364767-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD2BP2, DCLRE1A, EPCAM | NPY4R 4709/4885NPY1R 4482/4885NPY5R 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.